TPWA
ADMS

TRUE Private Wealth Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

TRUE Private Wealth Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-200
Closed -$1K – 788
2019
Q2 		$1K Buy
+200
New +$1.15K ﹤0.01% 779

Other funds holding ADMS

Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TRUE Private Wealth Advisors's ADMS Position: Q3 2019 in Review

TRUE Private Wealth Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q3 2019, closing a stake of 200 shares — an estimated $1K sold.

TRUE Private Wealth Advisors first reported a position in ADMS in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 87 funds tracked by Wall St. Rank hold ADMS as of Q3 2019.

  • TRUE Private Wealth Advisors reported no remaining Adamas Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • TRUE Private Wealth Advisors sold 200 Adamas Pharmaceuticals shares in Q3 2019, an estimated $1K.
  • TRUE Private Wealth Advisors first reported a position in Adamas Pharmaceuticals in Q2 2019 and held it in 1 quarter.
  • TRUE Private Wealth Advisors's Adamas Pharmaceuticals position peaked at $1K in Q2 2019.
  • 87 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2019.

Based on TRUE Private Wealth Advisors's 13F filing for Q3 2019, filed 9 Oct 2019.